Allow me a flippant response, "nothing." Looking at some of the papers that W. Ian Lipkin has published he's been working on this for a while.
So as a researcher he provides data which the FDA will use to assess accuracy and viability, meanwhile Columbia will probably lease out the patents (https://patentimages.storage.googleapis.com/pdfs/US200600033...) when it issues to a diagnostics company, perhaps to Elizabeth Holmes company (http://www.wired.com/2014/02/elizabeth-holmes-theranos/) who will then create a cost effective way to put this into drug stores everywhere, and when you're feeling bad you go in, prick your thumb, and get a text message of everything you might be sick with.
So as a researcher he provides data which the FDA will use to assess accuracy and viability, meanwhile Columbia will probably lease out the patents (https://patentimages.storage.googleapis.com/pdfs/US200600033...) when it issues to a diagnostics company, perhaps to Elizabeth Holmes company (http://www.wired.com/2014/02/elizabeth-holmes-theranos/) who will then create a cost effective way to put this into drug stores everywhere, and when you're feeling bad you go in, prick your thumb, and get a text message of everything you might be sick with.